Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-exploration study of MT2004 capsules for acute cholestatic or mixed drug-induced liver injury
CTR20232066Phase 2Active
- Sponsor
- Xi'an Aolitai Pharmaceutical Technology
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT2004 in Drug-induced hepatitis (DILI), sponsored by Xi'an Aolitai Pharmaceutical Technology. Started Dec 2023; status: active.
02
Drugs
MT2004
03
Conditions
Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on CTR20232066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232066.